FDAnews
www.fdanews.com/articles/101609-court-dismisses-apotex-s-cosopt-exclusivity-counterclaims-against-merck

Court Dismisses Apotex's Cosopt Exclusivity Counterclaims Against Merck

November 29, 2007
Merck has sold Cosopt (dorzolamide hydrochloride/timolol maleate), an opthalmic drug indicated for the treatment of ocular hypertension and open-angle glaucoma, since 1998. In October 2005, Hi-Tech Pharmacal filed the first ANDA for a generic version of Cosopt with paragraph IV certifications to the Orange Book-listed patents: U.S. Patent Nos. 4,797,413; 6,248,735; and 6,316,443.
Seeking Alpha